San Diego, CA -- (SBWIRE) -- 04/11/2017 -- Innoviva Inc is under investigation over potential securities laws violations. The investigation was announced for investors in NASDAQ:INVA shares in connection certain financial statements made by Innoviva Inc.

Investors who purchased shares of Innoviva Inc (NASDAQ:INVA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements by Innoviva Inc (NASDAQ:INVA regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Brisbane, CA based Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva Inc reported that its annual Total Revenue rose from $8.43 million in 2014 to $133.57 million in 2016 and that its Net Loss of $168.46 million in 2014 turned into a Net Income of $59.54 million in 2016.

Shares of Innoviva Inc (NASDAQ:INVA) grew from $7.68 per share in September 2015 to as high as $14.08 per share on April 10, 2017.

Those who purchased shares of Innoviva Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com